Molecular pathways in peritoneal fibrosis
MS Balzer - Cellular signalling, 2020 - Elsevier
Peritoneal dialysis (PD) is a renal replacement therapy for patients with end-stage renal
disease that is equivalent to hemodialysis with respect to adequacy, mortality, and other …
disease that is equivalent to hemodialysis with respect to adequacy, mortality, and other …
Fibrosis of peritoneal membrane as target of new therapies in peritoneal dialysis
V Masola, M Bonomini, S Borrelli, L Di Liberato… - International journal of …, 2022 - mdpi.com
Peritoneal dialysis (PD) is an efficient renal replacement therapy for patients with end-stage
renal disease. Even if it ensures an outcome equivalent to hemodialysis and a better quality …
renal disease. Even if it ensures an outcome equivalent to hemodialysis and a better quality …
SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose …
MS Balzer, S Rong, J Nordlohne, JD Zemtsovski… - Biomolecules, 2020 - mdpi.com
Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis,
angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically …
angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically …
Novel aspects of the immune response involved in the peritoneal damage in chronic kidney disease patients under dialysis
F Trionfetti, V Marchant, GT González-Mateo… - International Journal of …, 2023 - mdpi.com
Chronic kidney disease (CKD) incidence is growing worldwide, with a significant percentage
of CKD patients reaching end-stage renal disease (ESRD) and requiring kidney …
of CKD patients reaching end-stage renal disease (ESRD) and requiring kidney …
Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling
Y Shentu, Y Li, S Xie, H Jiang, S Sun, R Lin… - International …, 2021 - Elsevier
Abstract Sodium glucose cotransporter-2 (SGLT-2) inhibitor has been reported to exert a
glucose-lowering effect in the peritoneum exposed to peritoneal dialysis solution. However …
glucose-lowering effect in the peritoneum exposed to peritoneal dialysis solution. However …
Monocyte chemoattractant protein‐1 predicts the development of diabetic nephropathy
FG Scurt, J Menne, S Brandt… - Diabetes/Metabolism …, 2022 - Wiley Online Library
Aim Diabetic nephropathy (DN) is a devastating complication of diabetes mellitus (DM).
Therefore, screening strategies in order to prevent its development and/or retard its …
Therefore, screening strategies in order to prevent its development and/or retard its …
[HTML][HTML] CX3CL1–CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis
A Helmke, J Nordlohne, MS Balzer, L Dong, S Rong… - Kidney international, 2019 - Elsevier
Peritoneal dialysis (PD) is limited by chronic fibrotic remodeling of the peritoneal wall, a
transforming growth factor-β (TGF-β)-mediated process. The fractalkine (CX3CL1) receptor …
transforming growth factor-β (TGF-β)-mediated process. The fractalkine (CX3CL1) receptor …
[HTML][HTML] A review of research progress on mechanisms of peritoneal fibrosis related to peritoneal dialysis
J Li, Y Liu, J Liu - Frontiers in Physiology, 2023 - frontiersin.org
Peritoneal dialysis (PD) is an effective alternative treatment for patients with end-stage renal
disease (ESRD) and is increasingly being adopted and promoted worldwide. However, as …
disease (ESRD) and is increasingly being adopted and promoted worldwide. However, as …
Advanced oxidation protein products aggravate tubulointerstitial fibrosis through protein kinase C-dependent mitochondrial injury in early diabetic nephropathy
X Li, L Xu, X Hou, J Geng, J Tian, X Liu… - Antioxidants & redox …, 2019 - liebertpub.com
Aims: Diabetic nephropathy (DN) is the most common microvascular complications and the
principal cause of mortality and morbidity rates in patients with diabetes. The expression of …
principal cause of mortality and morbidity rates in patients with diabetes. The expression of …
TLR4 response to LPS is reinforced by urokinase receptor
Y Kiyan, S Tkachuk, S Rong, A Gorrasi… - Frontiers in …, 2020 - frontiersin.org
GPI-anchored uPAR is the receptor for the extracellular serine protease urokinase-type
plasminogen activator (uPA). Though uPAR role in inflammatory processes is documented …
plasminogen activator (uPA). Though uPAR role in inflammatory processes is documented …